阿仑单抗相关急性血栓性微血管病与肾皮质坏死一例
本文报告一例39岁复发缓解型多发性硬化女性患者,在接受1剂阿仑单抗后出现需肾脏替代治疗的急性肾损伤、微血管病性溶血性贫血和血小板减少。肾活检示广泛皮质坏死和小动脉纤维蛋白血栓,符合急性血栓性微血管病。经地塞米松和血浆置换治疗,血浆置换未能清除阿仑单抗,患者接受约7周肾脏替代治疗后肾功能逐渐恢复至接近基线。
要点
- 阿仑单抗可致急性血栓性微血管病伴肾皮质坏死,表现为急性肾损伤、微血管病性溶血性贫血和血小板减少。
- 肾活检示广泛皮质坏死和小动脉纤维蛋白血栓,免疫荧光IgM和C3非特异性染色,电镜无免疫复合物沉积。
- 血浆置换未能清除阿仑单抗,患者需约7周肾脏替代治疗,肾功能最终恢复至接近基线。
核心结论
- 阿仑单抗可诱发急性血栓性微血管病伴肾皮质坏死,导致需肾脏替代治疗的急性肾损伤。
研究设计与样本
- 单例病例报告:39岁复发缓解型多发性硬化女性,接受1剂阿仑单抗后发病。
主要发现
- 用药后出现急性肾损伤需肾脏替代治疗,伴微血管病性溶血性贫血和血小板减少。
- 肾活检示广泛皮质坏死和小动脉纤维蛋白血栓,免疫荧光IgM和C3非特异性染色,电镜无免疫复合物沉积。
- 血浆置换未能清除阿仑单抗,肾脏替代治疗约7周后肾功能逐渐恢复至接近基线。
临床怎么用
- 使用阿仑单抗后出现急性肾损伤伴微血管病性溶血性贫血和血小板减少时,应警惕药物性血栓性微血管病。
- 肾活检有助于明确急性血栓性微血管病和皮质坏死诊断。
- 血浆置换未能清除阿仑单抗,但肾脏替代治疗和支持治疗后肾功能可逐渐恢复。
局限性
- 单例病例报告,因果关系推断受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alemtuzumab, a humanized monoclonal antibody that targets CD52 antigens on lymphocytes and monocytes, has shown efficacy in preventing relapse in relapsing-remitting multiple sclerosis. Despite known severe (yet rare) renal side effects such as anti-glomerular basement membrane disease and membranous glomerulopathy, to our knowledge, alemtuzumab has never been documented to cause drug-induced thrombotic microangiopathy. We describe a 39-year-old woman with relapsing-remitting multiple sclerosis who developed acute kidney injury requiring renal replacement therapy after 1 dose of alemtuzumab, as well as microangiopathic hemolytic anemia and thrombocytopenia. Pathologic examination of a kidney biopsy specimen demonstrated extensive cortical necrosis and arteriolar fibrin thrombi with nonspecific immunofluorescence staining of immunoglobulin M and C3 and absence of immune deposits on electron microscopy. These findings were consistent with the diagnosis of acute thrombotic microangiopathy. She received dexamethasone and underwent plasmapheresis, which was unsuccessful at removing alemtuzumab. The patient received renal replacement therapy for approximately 7 weeks, followed by slow recovery of kidney function that returned close to her baseline.
引用
- Liou AA, Skiver BM, Yates E, et al. Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report. Am J Kidney Dis. 2018. PMID: 30528935. doi:10.1053/j.ajkd.2018.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。